OMGAQ
Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epig… Read more
OMGAQ (OMGAQ) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2024: -1.214x
Based on the latest financial reports, OMGAQ (OMGAQ) has a cash flow conversion efficiency ratio of -1.214x as of September 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.02 Million) by net assets ($11.54 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
OMGAQ - Cash Flow Conversion Efficiency Trend (2020–2023)
This chart illustrates how OMGAQ's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
OMGAQ Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of OMGAQ ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
IA Invest Advice Cap Vis Fund
CO:IAIACVF
|
N/A |
|
Springer Nature AG & Co KGaA
XETRA:SPG
|
N/A |
|
Fidelity Global Balanced Portfolio
TO:FMPB
|
N/A |
|
MEDIOBANCA
BE:ME9
|
N/A |
|
AMN HEALTHCARE (HCQ.SG)
STU:HCQ
|
0.075x |
|
Kyeryong Construction Industrial Co. Ltd.
KQ:013580
|
N/A |
|
MIZUNO
BE:MIZ
|
N/A |
|
African Media Entertainment
JSE:AME
|
0.070x |
Annual Cash Flow Conversion Efficiency for OMGAQ (2020–2023)
The table below shows the annual cash flow conversion efficiency of OMGAQ from 2020 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $58.02 Million | $-91.51 Million | -1.577x | -69.67% |
| 2022-12-31 | $105.97 Million | $-98.52 Million | -0.930x | -223.76% |
| 2021-12-31 | $200.63 Million | $-57.61 Million | -0.287x | -171.01% |
| 2020-12-31 | $-64.63 Million | $-26.13 Million | 0.404x | -- |